A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy

While recognized as the first effective immunotherapy for human cancer, IL-2 based immunotherapy still encounters several limitations in the clinic. Here, the authors design a cytokine receptor-masked IL-2 mutein prodrug that is selectively activated by matrix metalloproteinases in the tumor microen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eric J. Hsu, Xuezhi Cao, Benjamin Moon, Joonbeom Bae, Zhichen Sun, Zhida Liu, Yang-Xin Fu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/6463d0ebf5724fa3841e56e2d6aac28f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6463d0ebf5724fa3841e56e2d6aac28f
record_format	dspace
spelling	oai:doaj.org-article:6463d0ebf5724fa3841e56e2d6aac28f2021-12-02T16:50:30ZA cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy10.1038/s41467-021-22980-w2041-1723https://doaj.org/article/6463d0ebf5724fa3841e56e2d6aac28f2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22980-whttps://doaj.org/toc/2041-1723While recognized as the first effective immunotherapy for human cancer, IL-2 based immunotherapy still encounters several limitations in the clinic. Here, the authors design a cytokine receptor-masked IL-2 mutein prodrug that is selectively activated by matrix metalloproteinases in the tumor microenvironment, promoting anti-tumor immune response while minimizing systemic toxicity.Eric J. HsuXuezhi CaoBenjamin MoonJoonbeom BaeZhichen SunZhida LiuYang-Xin FuNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Eric J. Hsu Xuezhi Cao Benjamin Moon Joonbeom Bae Zhichen Sun Zhida Liu Yang-Xin Fu A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
description	While recognized as the first effective immunotherapy for human cancer, IL-2 based immunotherapy still encounters several limitations in the clinic. Here, the authors design a cytokine receptor-masked IL-2 mutein prodrug that is selectively activated by matrix metalloproteinases in the tumor microenvironment, promoting anti-tumor immune response while minimizing systemic toxicity.
format	article
author	Eric J. Hsu Xuezhi Cao Benjamin Moon Joonbeom Bae Zhichen Sun Zhida Liu Yang-Xin Fu
author_facet	Eric J. Hsu Xuezhi Cao Benjamin Moon Joonbeom Bae Zhichen Sun Zhida Liu Yang-Xin Fu
author_sort	Eric J. Hsu
title	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
title_short	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
title_full	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
title_fullStr	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
title_full_unstemmed	A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
title_sort	cytokine receptor-masked il2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6463d0ebf5724fa3841e56e2d6aac28f
work_keys_str_mv	AT ericjhsu acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT xuezhicao acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT benjaminmoon acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT joonbeombae acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT zhichensun acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT zhidaliu acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT yangxinfu acytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT ericjhsu cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT xuezhicao cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT benjaminmoon cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT joonbeombae cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT zhichensun cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT zhidaliu cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy AT yangxinfu cytokinereceptormaskedil2prodrugselectivelyactivatestumorinfiltratinglymphocytesforpotentantitumortherapy
_version_	1718383042018410496

A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy

Ejemplares similares